PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models ...

Chemotherapy-induced nausea and vomiting (CINV) remains a significant barrier to treatment adherence and quality of life in cervical cancer patients receiving chemoradiotherapy. No validated ...

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors ...

Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial. This is an ASCO Meeting Abstract from the 2025 ...

Certis Oncology, an AI-enabled translational science company, today announced the launch of Certis Oncology Intelligence®, an integrated platform designed to generate data-driven insights into ...

Liver cancer is one of the world's deadliest malignancies, ranking as the third leading cause of cancer-related death. While advances in surgery have improved safety, recurrence after hepatectomy ...

Breast cancer is a biologically heterogeneous disease in which genomic complexity, dynamic tumor evolution, and variable therapeutic response continue to ...

Prediction of 48-hour intensive care unit mortality in hospitalized cancer patients: Accuracy of the EPIC deterioration index and sequential organ failure assessment score. This is an ASCO Meeting ...

Before we begin, let me quickly remind you that during the course of this presentation, the company will make forward-looking statements. We caution you that any statement that is not a statement of ...